Business

Eli Lilly to Report Earnings, Fueled by Key Drugs

Updated 2026-10-29 10:20 UTC 1 source Neutral

Pharmaceutical giant Eli Lilly is set to report third-quarter earnings, driven primarily by its obesity drug Zepbound and diabetes medication Mounjaro. Analysts are closely watching the results for signs of continued growth in these key areas.

Coverage timeline — 1 article

CNBC

Eli Lilly is about to report earnings. Here's what to expect

Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.

2026-10-29 10:13 UTC